TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
40.06
+0.76 (1.93%)
At close: Jun 6, 2025, 4:00 PM
40.00
-0.06 (-0.15%)
After-hours: Jun 6, 2025, 5:59 PM EDT

TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of $5.84 billion. The enterprise value is $5.79 billion.

Market Cap 5.84B
Enterprise Value 5.79B

Important Dates

The last earnings date was Monday, May 5, 2025, before market open.

Earnings Date May 5, 2025
Ex-Dividend Date n/a

Share Statistics

TG Therapeutics has 145.82 million shares outstanding. The number of shares has increased by 9.66% in one year.

Current Share Class 145.82M
Shares Outstanding 145.82M
Shares Change (YoY) +9.66%
Shares Change (QoQ) +1.58%
Owned by Insiders (%) 7.29%
Owned by Institutions (%) 71.72%
Float 135.13M

Valuation Ratios

The trailing PE ratio is 168.22 and the forward PE ratio is 34.49. TG Therapeutics's PEG ratio is 0.30.

PE Ratio 168.22
Forward PE 34.49
PS Ratio 14.79
Forward PS 12.04
PB Ratio 24.05
P/TBV Ratio 24.48
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio 0.30
Financial Ratio History

Enterprise Valuation

EV / Earnings 147.83
EV / Sales 14.98
EV / EBITDA 96.67
EV / EBIT 96.75
EV / FCF n/a

Financial Position

The company has a current ratio of 4.02, with a Debt / Equity ratio of 1.07.

Current Ratio 4.02
Quick Ratio 2.91
Debt / Equity 1.07
Debt / EBITDA 4.10
Debt / FCF n/a
Interest Coverage 2.10

Financial Efficiency

Return on equity (ROE) is 19.70% and return on invested capital (ROIC) is 9.79%.

Return on Equity (ROE) 19.70%
Return on Assets (ROA) 7.26%
Return on Invested Capital (ROIC) 9.79%
Return on Capital Employed (ROCE) 12.05%
Revenue Per Employee $1.14M
Profits Per Employee $115,828
Employee Count 338
Asset Turnover 0.75
Inventory Turnover 0.41

Taxes

In the past 12 months, TG Therapeutics has paid $2.59 million in taxes.

Income Tax 2.59M
Effective Tax Rate 6.21%

Stock Price Statistics

The stock price has increased by +142.35% in the last 52 weeks. The beta is 1.94, so TG Therapeutics's price volatility has been higher than the market average.

Beta (5Y) 1.94
52-Week Price Change +142.35%
50-Day Moving Average 37.46
200-Day Moving Average 31.48
Relative Strength Index (RSI) 64.97
Average Volume (20 Days) 1,848,711

Short Selling Information

The latest short interest is 22.57 million, so 15.48% of the outstanding shares have been sold short.

Short Interest 22.57M
Short Previous Month 23.11M
Short % of Shares Out 15.48%
Short % of Float 16.70%
Short Ratio (days to cover) 7.33

Income Statement

In the last 12 months, TG Therapeutics had revenue of $386.39 million and earned $39.15 million in profits. Earnings per share was $0.24.

Revenue 386.39M
Gross Profit 337.80M
Operating Income 59.82M
Pretax Income n/a
Net Income 39.15M
EBITDA 59.87M
EBIT 59.82M
Earnings Per Share (EPS) $0.24
Full Income Statement

Balance Sheet

The company has $276.24 million in cash and $254.58 million in debt, giving a net cash position of $21.66 million or $0.15 per share.

Cash & Cash Equivalents 276.24M
Total Debt 254.58M
Net Cash 21.66M
Net Cash Per Share $0.15
Equity (Book Value) 237.29M
Book Value Per Share 1.63
Working Capital 484.30M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$61.03 million and capital expenditures -$70,000, giving a free cash flow of -$61.10 million.

Operating Cash Flow -61.03M
Capital Expenditures -70,000
Free Cash Flow -61.10M
FCF Per Share -$0.42
Full Cash Flow Statement

Margins

Gross margin is 87.43%, with operating and profit margins of 15.48% and 10.13%.

Gross Margin 87.43%
Operating Margin 15.48%
Pretax Margin 10.80%
Profit Margin 10.13%
EBITDA Margin 15.49%
EBIT Margin 15.48%
FCF Margin n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -9.66%
Shareholder Yield -9.66%
Earnings Yield 0.67%
FCF Yield -1.05%
Dividend Details

Analyst Forecast

The average price target for TG Therapeutics is $40.80, which is 1.85% higher than the current price. The consensus rating is "Strong Buy".

Price Target $40.80
Price Target Difference 1.85%
Analyst Consensus Strong Buy
Analyst Count 5
Revenue Growth Forecast (5Y) 36.90%
EPS Growth Forecast (5Y) 100.29%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on April 30, 2012. It was a reverse split with a ratio of 0.0177777:1.

Last Split Date Apr 30, 2012
Split Type Reverse
Split Ratio 0.0177777:1

Scores

TG Therapeutics has an Altman Z-Score of 3.66 and a Piotroski F-Score of 3.

Altman Z-Score 3.66
Piotroski F-Score 3